• The Journal of Korean Obstetrics and Gynecology
• /
• v.20 no.4
• /
• pp.225-233
• /
• 2007

Purpose: The purpose of this study Is to report the effect of Paljeongsangami(八正散加味) on the female urethral syndrome(FUS). Methods: A subject was a 29-year-old woman who suffered from FUS even after the treatment of western medicine. We evaluated the routine blood test. U/A, Pap smear and N.gonorrhoeae PCR, but there were no abnormal findings. We gave her Paljeongsangami 3 times a day for 10 days with acupuncture and moxibustion. During the treatment, we asked her complete a urinary dairy. Results: After the treatment, the symptoms of FUS was disappeared and her condition was maintained for 2 months at least. Conclusion: This case report showed that Paljeongsangami is efficacious for FUS and could prevent chronic progress and relapse of symptoms. More clinical data and studies are to be done for the effective application of the various oriental medicinal therapy on FUS.

• Journal of Chest Surgery
• /
• v.17 no.3
• /
• pp.389-397
• /
• 1984

Sixty cases of open heart surgery were performed in the Department of Thoracic and Cardiovascular Surgery of Chonbuk National University Hospital from July, 1983 to June, 1984. The patients were consisted of 40 [66%] congenital anomalies containing 26 [43%] patients of acyanotic group and 4 [23%] of cyanotic group, and 20 [34%] acquired heart diseases which involved one or more cardiac valves. The male patients were 42 and the female 18. In 20 valvular heart diseases, open mitral commissurotomy was done in 5 patients, mitral valvular replacement with tissue valve in 6, mitral valvular replacement with mechanical valve in 5, mitral valvular replacement with tricuspid annuloplasty in 2, mitral annuloplasty in 1, and mitral and aortic valvular replacements with mechanical valves in 1. The most frequency complication was low cardiac output syndrome occurred in 9, and the next was urethral stenosis, ARDS, and postoperative bleeding, etc. The perioperative mortality was 21% in congenital cyanotic heart disease, 12% in congenital acyanotic heart disease, and 5% in acquired heart disease.